S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy

Send us a text Key Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices. This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs ...

Jaksot(1066)

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-poliisin-mieli
utelias-mieli
rss-duodecim-lehti
tiedekulma-podcast
rss-bios-podcast
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
hippokrateen-vastaanotolla
rss-ammamafia
rss-mental-race
rss-ylistys-elaimille
university-of-eastern-finland
docemilia
rss-laakaripodi
rss-metsanomistaja-podcast
vinkista-vihia
mielipaivakirja
radio-antro
rss-kipinoita-podcast
rss-hengenpelastajat